Life Sciences

Marlborough medical device manufacturer Boston Scientific has voluntarily recalled the unused inventory of one of its aortic valve systems and announced it will discontinue the product.

A German biologics company has chosen a Boxborough site for a $150-million virotherapy manufacturing center spanning 110,000 square feet in what the company says is a major expansion of its United States operations.

Marlborough drugmaker Phio Pharmaceuticals has ended the third quarter of the year with $16.9 million on hand as it ramps up its research and development of its cancer therapy technology.

Framingham biotech company Arch Therapeutics has raised $1.1 million from long-term shareholders, the company announced on Tuesday.

Framingham drug developer Sanofi’s new facility has received acclaim for its design, construction and operation from the International Society for Pharmaceutical Engineering.

Holliston’s Harvard Bioscience has continued to correct course in the third quarter of the year after a rocky start to the year saw the company lose $4.5-million loss in the first quarter, according to its earnings report from Wednesday.

Acton medical device company Insulet has reported a 1,350% increase in profits in its third quarter, compared to the same time period last year, logging $11.6 million in profits compared to $0.8 million during the same time period last year. 

Diagnostic company Oxford Immunotec, which has U.S. headquarters in Marlborough, reported a $149,000 loss in net income in the company’s third quarter, according to an earnings report released on Tuesday.

The Sartorius Group has announced that it will create 100 jobs in Marlborough when it launches its new North American Customer Interaction Center.

Milford life sciences company Waters Corp. reported a 8.2% decrease in revenue during the company’s third quarter, according to an earnings report published Tuesday.